Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) Target Price at $25.50

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) have been assigned a consensus rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $25.50.

A number of analysts have recently commented on VERV shares. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Royal Bank of Canada lowered their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. Guggenheim reaffirmed a “buy” rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Finally, William Blair reiterated an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its stake in Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after acquiring an additional 3,964 shares during the period. IFP Advisors Inc increased its stake in shares of Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after purchasing an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics during the fourth quarter worth about $50,000. Erste Asset Management GmbH purchased a new position in Verve Therapeutics in the 3rd quarter valued at about $56,000. Finally, Impact Partnership Wealth LLC acquired a new stake in Verve Therapeutics in the 4th quarter worth about $70,000. 97.11% of the stock is owned by institutional investors and hedge funds.

Verve Therapeutics Trading Down 12.5 %

Shares of NASDAQ VERV opened at $4.57 on Tuesday. The stock has a market cap of $405.80 million, a price-to-earnings ratio of -1.86 and a beta of 1.77. Verve Therapeutics has a 12 month low of $4.31 and a 12 month high of $13.24. The company has a 50 day simple moving average of $6.91 and a two-hundred day simple moving average of $6.08.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Analysts forecast that Verve Therapeutics will post -2.49 EPS for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.